TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $334,740 | -26.2% | 37,443 | +26.8% | 0.00% | – |
| Q2 2023 | $453,412 | -18.1% | 29,519 | +19.9% | 0.00% | – |
| Q1 2023 | $553,906 | +7.7% | 24,629 | +0.7% | 0.00% | – |
| Q4 2022 | $514,394 | -96.2% | 24,460 | -95.5% | 0.00% | -100.0% |
| Q3 2022 | $13,398,961 | +1.6% | 543,789 | -0.1% | 0.01% | 0.0% |
| Q2 2022 | $13,188,219 | -5.9% | 544,293 | +0.0% | 0.01% | 0.0% |
| Q1 2022 | $14,020,065 | -16.9% | 544,046 | -1.0% | 0.01% | -10.0% |
| Q4 2021 | $16,871,000 | -1.4% | 549,488 | -22.2% | 0.01% | -28.6% |
| Q3 2021 | $17,119,000 | +65.4% | 705,925 | -0.5% | 0.01% | +75.0% |
| Q2 2021 | $10,351,000 | -82.1% | 709,502 | -69.3% | 0.01% | -84.0% |
| Q1 2021 | $57,678,000 | -3.2% | 2,309,887 | +5.6% | 0.05% | -9.1% |
| Q4 2020 | $59,603,000 | – | 2,186,830 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |